A multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis.
- Type of Study
- Neuroscience - Multiple Sclerosis
- Cherry Hill Campus
- Short Description
The purpose of this study is to assess the effect of two different doses of the drug teriflunomide compared to a placebo on the frequency of relapses of multiple sclerosis (MS) in patients with the relapsing form of MS. The study will also look at the effect of two different doses of teriflunomide compared to a placebo in terms of the progression of disability caused by relapsing MS, as well as fatigue and quality of life. Finally, the study will evaluate the safety of the drug and how well patients tolerate the different dosages.
- Submitted for Study Approval
- Principal Investigator
- Lily Jung, MD
- Eligibility Notes
Study patients must be older than 18 or younger than 56 years of age.
Must have a relapsing form of multiple sclerosis (MS) based on McDonald's diagnosis criteria.
Must have an EDSS score of less than 6.
Must have had one relapse within the past 12 months before being randomized, or
Two relapses within the past 24 months before being randomized.
- Contact Name
- Megan Alexander, Study Coordinator
- Alternate Phone
- Alternate Email